-
1.发明申请公开(公告)号：US20130157298A1
公开(公告)日：2013-06-20
申请号：US13607402
申请日：2012-09-07
申请人： Aleksandr Kolesnikov , Roopa Rai , William Dvorak Shrader , Steven M. Torkelson , Kieron E. Wesson , Wendy B. Young
发明人： Aleksandr Kolesnikov , Roopa Rai , William Dvorak Shrader , Steven M. Torkelson , Kieron E. Wesson , Wendy B. Young
IPC分类号： C12Q1/56
CPC分类号： C07D235/18 , C07D235/12 , C07D235/16 , C07D401/12 , C07D403/10 , C07F9/094 , C07F9/12 , C07F9/65128 , C12Q1/56
摘要： The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
-
公开(公告)号：US20120130093A1
公开(公告)日：2012-05-24
申请号：US13358451
申请日：2012-01-25
IPC分类号： C07D311/72
CPC分类号： C07D311/72 , C07C46/02 , C07C50/28
摘要： The invention discloses novel processes for production, enrichment and/or isolation of alpha-tocotrienol from source material comprising at least one non-alpha-tocotrienol, such as natural extracts comprising mixed tocotrienols.
摘要翻译： 本发明公开了从源材料生产，富集和/或分离α-生育三烯酚的新方法，其包含至少一种非α-生育三烯酚，例如包含混合的生育三烯酚的天然提取物。
-
公开(公告)号：US08106223B2
公开(公告)日：2012-01-31
申请号：US12606923
申请日：2009-10-27
IPC分类号： C07D311/72 , C07C50/06
CPC分类号： C07D311/72 , C07C46/02 , C07C50/28
摘要： The invention discloses novel processes for production, enrichment and/or isolation of alpha-tocotrienol from source material comprising at least one non-alpha-tocotrienol, such as natural extracts comprising mixed tocotrienols.
摘要翻译： 本发明公开了从源材料生产，富集和/或分离α-生育三烯酚的新方法，其包含至少一种非α-生育三烯酚，例如包含混合的生育三烯酚的天然提取物。
-
4.发明授权4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases 有权4-（对醌基）-2-羟基丁酰胺衍生物用于治疗线粒体疾病公开(公告)号：US07968746B2
公开(公告)日：2011-06-28
申请号：US12264838
申请日：2008-11-04
IPC分类号： C07C233/00
CPC分类号： C07C235/80 , C07C235/78 , C07C317/28 , C07C2601/02 , C07C2601/16 , C07D207/26 , C07D207/27 , C07D211/46 , C07D213/40 , C07D213/50 , C07D233/61 , C07D265/30 , C07D295/116 , C07D295/13 , C07D295/185 , C07D295/192 , C07D311/66
摘要： Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.
摘要翻译： 还公开了治疗或抑制线粒体疾病如弗里德里希共济失调（FRDA），Leber氏遗传性视神经病变（LHON），线粒体肌病，脑病，乳酸脱落和中风（MELAS），Kearns-Sayre综合征（KSS）的方法 作为可用于本发明方法的化合物，例如4-（对 - 喹啉基）-2-羟基丁酰胺衍生物。 还公开了可用于治疗其他疾病如肌萎缩性侧索硬化（ALS），亨廷顿氏病，帕金森病和普遍发育障碍如自闭症的方法和化合物。 还公开了可用于评估受试者的代谢状态和治疗功效的能量生物标志物。 还公开了调节，归一化或增强能量生物标志物的方法以及可用于这些方法的化合物。
-
5.发明申请4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES 有权4-（对 - 喹啉）-2-羟基丁酰胺衍生物用于治疗麻醉性疾病公开(公告)号：US20090118257A1
公开(公告)日：2009-05-07
申请号：US12264838
申请日：2008-11-04
IPC分类号： A61K31/16 , C07C235/72 , C07D211/06 , C07D223/02 , A61K31/55 , A61K31/445 , A61K31/4164 , A61K31/495 , C07D233/54 , C07D241/04 , A61P25/00
CPC分类号： C07C235/80 , C07C235/78 , C07C317/28 , C07C2601/02 , C07C2601/16 , C07D207/26 , C07D207/27 , C07D211/46 , C07D213/40 , C07D213/50 , C07D233/61 , C07D265/30 , C07D295/116 , C07D295/13 , C07D295/185 , C07D295/192 , C07D311/66
摘要： Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.
摘要翻译： 还公开了治疗或抑制线粒体疾病如弗里德里希共济失调（FRDA），Leber氏遗传性视神经病变（LHON），线粒体肌病，脑病，乳酸脱落和中风（MELAS），Kearns-Sayre综合征（KSS）的方法 作为可用于本发明方法的化合物，例如4-（对 - 喹啉基）-2-羟基丁酰胺衍生物。 还公开了可用于治疗其他疾病如肌萎缩性侧索硬化（ALS），亨廷顿氏病，帕金森病和普遍发育障碍如自闭症的方法和化合物。 还公开了可用于评估受试者的代谢状态和治疗功效的能量生物标志物。 还公开了调节，归一化或增强能量生物标志物的方法以及可用于这些方法的化合物。
-
6.发明授权2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors 有权2-（2-羟基联苯-3-基）-1H-苯并咪唑-5-甲脒衍生物作为因子VIIA抑制剂公开(公告)号：US07479502B2
公开(公告)日：2009-01-20
申请号：US10537115
申请日：2003-12-03
申请人： Aleksandr Kolesnikov , Roopa Rai , William Dvorak Shrader , Steven M. Torkelson , Kieron E. Wesson , Wendy B. Young
发明人： Aleksandr Kolesnikov , Roopa Rai , William Dvorak Shrader , Steven M. Torkelson , Kieron E. Wesson , Wendy B. Young
IPC分类号： A61K31/4184 , C07D235/18
CPC分类号： C07D235/18 , C07D235/12 , C07D235/16 , C07D401/12 , C07D403/10 , C07F9/094 , C07F9/12 , C07F9/65128 , C12Q1/56
摘要： The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
摘要翻译： 本发明涉及因子VIIa，IXa，Xa，XIa，特别是因子VIIa的新型抑制剂，包含这些抑制剂的药物组合物，以及使用这些抑制剂治疗或预防血栓栓塞性疾病，癌症或类风湿性关节炎的方法。 还公开了制备这些抑制剂的方法。
-
7.发明授权Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers 有权用于治疗线粒体疾病和其他条件的氧化还原活性治疗剂的侧链变体和能量生物标志物的调节公开(公告)号：US09278085B2
公开(公告)日：2016-03-08
申请号：US11710042
申请日：2007-02-22
IPC分类号： A61K31/355 , A61K31/05 , C07C39/08 , C07C39/11 , C07C39/19 , C07C39/24 , C07C50/02 , C07C50/06 , C07C50/24 , C07C50/28 , C07C215/56 , C07C403/04 , C07C403/08 , C07C403/18
CPC分类号： C07C50/04 , A61K31/05 , A61K31/355 , C07C39/08 , C07C39/11 , C07C39/19 , C07C39/245 , C07C43/225 , C07C43/23 , C07C47/277 , C07C50/02 , C07C50/06 , C07C50/24 , C07C50/28 , C07C69/608 , C07C69/618 , C07C215/56 , C07C233/27 , C07C233/32 , C07C255/37 , C07C403/04 , C07C403/08 , C07C403/18 , C07C2601/16
摘要： Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.
摘要翻译： 公开了治疗或抑制线粒体疾病如弗里德里希共济失调（FRDA），莱伯氏遗传性视神经病变（LHON），线粒体肌病，脑病，乳酸脱落症，中风（MELAS）或Kearns-Sayre综合征（KSS）的方法，以及 可用于本发明方法的化合物。 还公开了可用于治疗其它疾病的方法和化合物。 还公开了可用于评估受试者的代谢状态和治疗功效的能量生物标志物。 还公开了调节，归一化或增强能量生物标志物的方法以及可用于这些方法的化合物。
-
8.发明授权2-substituted-p-quinone derivatives for treatment of oxidative stress diseases 有权用于治疗氧化应激疾病的2-取代的对醌衍生物公开(公告)号：US08716527B2
公开(公告)日：2014-05-06
申请号：US12919007
申请日：2009-03-04
申请人： Andrew W. Hinman , Kieron E. Wesson , Orion D. Jankowski , Paul Mollard , William D. Shrader , Christopher R. Cornell
发明人： Andrew W. Hinman , Kieron E. Wesson , Orion D. Jankowski , Paul Mollard , William D. Shrader , Christopher R. Cornell
IPC分类号： C07C233/05 , A61K31/65 , C07D209/04 , C07D211/00 , A61K31/445 , A61K31/40
CPC分类号： C07D295/195 , A61P21/00 , A61P25/00 , C07C45/00 , C07C45/30 , C07C205/34 , C07C233/31 , C07C233/61 , C07C233/76 , C07C235/34 , C07C235/40 , C07C235/78 , C07C255/57 , C07C255/60 , C07C275/22 , C07C275/30 , C07C311/03 , C07C311/16 , C07C311/17 , C07C311/29 , C07C2601/02 , C07C2601/14 , C07C2601/16 , C07D209/08 , C07D211/46 , C07D213/56 , C07D213/75 , C07D213/82 , C07D215/08 , C07D217/06 , C07D295/215 , C07D311/74 , C07D317/66 , C07D319/18 , C07D339/04 , C07C47/575 , C07C47/277
摘要： Methods of treating or suppressing oxidative stress diseases including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases and diseases of aging are disclosed, as well as compounds useful in the methods of the invention, such as 2- substituted-p-quinone derivatives as disclosed herein.
摘要翻译： 公开了治疗或抑制包括线粒体疾病，受损能量加工障碍，神经变性疾病和衰老疾病的氧化应激疾病的方法，以及可用于本发明方法的化合物，例如所公开的2-取代对醌衍生物 这里。
-
9.发明申请2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS 有权作为因子VIIA抑制剂的2-（2-羟基联苯-3-基）-1H-苯并咪唑-5-羧酰胺衍生物公开(公告)号：US20110269806A1
公开(公告)日：2011-11-03
申请号：US13100107
申请日：2011-05-03
申请人： Aleksandr Kolesnikov , Roopa Rai , William Dvorak Shrader , Steven M. Torkelson , Kieron E. Wesson , Wendy B. Young
发明人： Aleksandr Kolesnikov , Roopa Rai , William Dvorak Shrader , Steven M. Torkelson , Kieron E. Wesson , Wendy B. Young
IPC分类号： A61K31/4184 , A61P7/00
CPC分类号： C07D235/18 , C07D235/12 , C07D235/16 , C07D401/12 , C07D403/10 , C07F9/094 , C07F9/12 , C07F9/65128 , C12Q1/56
摘要： The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
摘要翻译： 本发明涉及因子VIIa，IXa，Xa，XIa，特别是因子VIIa的新型抑制剂，包含这些抑制剂的药物组合物，以及使用这些抑制剂治疗或预防血栓栓塞性疾病，癌症或类风湿性关节炎的方法。 还公开了制备这些抑制剂的方法。
-
10.发明申请2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors 审中-公开2-（2-羟基联苯-3-基）-1H-苯并咪唑-5-甲脒衍生物作为因子VIIA抑制剂公开(公告)号：US20090054432A1
公开(公告)日：2009-02-26
申请号：US12255540
申请日：2008-10-21
申请人： Aleksandr KOLESNIKOV , Roopa Rai , William Dvorak Shrader , Steven M. Torkelson , Kieron E. Wesson , Wendy B. Young
发明人： Aleksandr KOLESNIKOV , Roopa Rai , William Dvorak Shrader , Steven M. Torkelson , Kieron E. Wesson , Wendy B. Young
IPC分类号： A61K31/5377 , A61K31/4184 , A61K31/4439 , A61P35/00 , A61K31/41 , A61K31/454
CPC分类号： C07D235/18 , C07D235/12 , C07D235/16 , C07D401/12 , C07D403/10 , C07F9/094 , C07F9/12 , C07F9/65128 , C12Q1/56
摘要： The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
摘要翻译： 本发明涉及因子VIIa，IXa，Xa，XIa，特别是因子VIIa的新型抑制剂，包含这些抑制剂的药物组合物，以及使用这些抑制剂治疗或预防血栓栓塞性疾病，癌症或类风湿性关节炎的方法。 还公开了制备这些抑制剂的方法。
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.032 秒)
